External broker reports(aggregated public sources), Taylor Collison

Taylor Collison

External broker reports(aggregated public sources)

Taylor Collison is a leading financial services firm, providing advice & wealth creation strategies to private & institutional investors and corporate clients throughout Australia. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul>
<li>PXS reported encouraging proof of concept data last month for its PXS-6302 skin scar treatment.</li>
<li>PXS-6302 reduced the excess collagen content in established scars by up to 50%.</li>
<li>While there was no overall improvement in scar appearance, this was not surprising given the average age of the scars treated (~13 years) and the short duration of treatment.</li>
</ul>
<p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>


PXS reported encouraging proof of concept data last month for its PXS-6302 skin scar treatment.
PXS-6302 reduced the excess collagen content in established scars by up to 50%.
While there was no overall improvement in scar appearance, this was not surprising given the average age of the scars treated (~13 years) and the short duration of treatment.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Pharmaxis (PXS) - Progressing to Next Stage in Scarring and Myelofibrosis

<ul><li>PXS announced that it will accelerate plans to investigate its anti-fibrosis drug PXS-5505 in combination with JAK inhibitors in myelofibrosis (MF).</li><li>It will expand its ongoing Phase II trial to include an additional combo therapy arm that will treat MF patients with PXS-5505 in addition to standard of care JAK inhibitor therapy.</li><li>The decision is based on feedback from the FDA, which has reviewed interim safety and efficacy information from the ongoing monotherapy MF trial.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

PXS announced that it will accelerate plans to investigate its anti-fibrosis drug PXS-5505 in combination with JAK inhibitors in myelofibrosis (MF).It will expand its ongoing Phase II trial to include an additional combo therapy arm that will treat MF patients with PXS-5505 in addition to standard of care JAK inhibitor therapy.The decision is based on feedback from the FDA, which has reviewed interim safety and efficacy information from the ongoing monotherapy MF trial.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Pharmaxis (PXS) - PXS-5505 to Progress to JAK Combo Trial

<div><div><div><ul><li>PXS continues to make good progress developing its drug candidates.</li><li>It has reported encouraging initial evidence that its anti-fibrosis drug PXS-6302 improves patient scars and is expected to report initial data from the ongoing trial of PXS-5505 in myelofibrosis (MF) before the end of the year.</li><li>It also recently added an externally-funded Phase II trial of PXS-4728 (handed back by Boehringer in 2020) in patients at high risk of Parkinson’s disease (PD). </li></ul></div></div></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

PXS continues to make good progress developing its drug candidates.It has reported encouraging initial evidence that its anti-fibrosis drug PXS-6302 improves patient scars and is expected to report initial data from the ongoing trial of PXS-5505 in myelofibrosis (MF) before the end of the year.It also recently added an externally-funded Phase II trial of PXS-4728 (handed back by Boehringer in 2020) in patients at high risk of Parkinson’s disease (PD). Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Pharmaxis (PXS) - Encouraging Initial Efficacy Data, Adding New Programs

Australia

Syntara Limited operates as a clinical stage drug development company. The Company develops therapeutic products for blood related cancers. Syntara serves customers in Australia.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Syntara (SNT AU)

Pharmaxis (PXS) - Progressing to Next Stage in Scarring and Myelofibrosis

PXS reported encouraging proof of concept data last month for its PXS-6302 skin scar treatment. PXS-6302 reduced the excess collagen content in...

Taylor Collison

Pharmaxis (PXS) - PXS-5505 to Progress to JAK Combo Trial

PXS announced that it will accelerate plans to investigate its anti-fibrosis drug PXS-5505 in combination with JAK inhibitors in myelofibrosis (MF).

Taylor Collison

Pharmaxis (PXS) - Encouraging Initial Efficacy Data, Adding New Programs

It also recently added an externally-funded Phase II trial of PXS-4728 (handed back by Boehringer in 2020) in patients at high risk of Parkinson’s...

Taylor Collison

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)